The institutional question is no longer whether self-experimentation is medically advisable; it is whether medicine can still claim full authority over experiments that technically capable patients can perform themselves. Halassy's case sits beside AI-assisted bespoke biotech stories because both convert scientific literacy into direct intervention, bypassing the committees and trial designs that normally translate risk into legitimacy. That does not make the intervention generalizable. It makes the approval system look slow precisely where patients feel time as the scarce resource.